[{"orgOrder":0,"company":"IN8bio","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"INB-200","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"IN8bio \/ Barclays","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Barclays"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"INB-200","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"DeltEx DRI Chlorotoxin CAR-T","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"INB-200","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"B. Riley Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Genetically Modified Autologous Gamma-delta T Cell therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ B. Riley Securities","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ B. Riley Securities"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Gamma Delta T-Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Gamma Delta T-Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Kansas Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Gamma Delta T-Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IN8bio \/ University of Kansas Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ University of Kansas Cancer Center"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"DeltEx DRI Chlorotoxin CAR-T","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Gamma Delta T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"DeltEx DRI Chlorotoxin CAR-T","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Alabama at Birmingham","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"INB-200","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ University of Alabama at Birmingham","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ University of Alabama at Birmingham"},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Louisville","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"INB-400","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ University of Louisville","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ University of Louisville"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"INB-400","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"INB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"INB-400","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"INB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"INB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"IN8bio \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Autologous Genetically Modified Gamma-delta T Cells","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"INB-400","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"INB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"INB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IN8bio \/ Not Applicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"INB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IN8bio","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IN8bio \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"14","companyTruncated":"IN8bio \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"INB-100","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"IN8bio \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by IN8bio
Details :
The financing will aim to advance the ongoing expansion cohorts of early-stage trial studies of INB-100 for patients with Acute Myeloid Leukemia.
Details :
INB-100, IN8bio’s DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with AML undergoing hematopoietic bone marrow transplantation.
Details :
INB-100 is a gamma-delta T-cell immunotherapy developed by IN8bio to treat patients with hematologic malignancies who have undergone a hematopoietic stem cell transplant (HSCT).
Details :
INB-100 is an allogeneic gamma-delta T-cell therapy, being evaluated for the treatment of high-risk & relapsed acute myeloid leukemia patients who had previously failed multiple lines of therapy.
Details :
INB-400 is an autologous gamma-delta T cell therapy product candidate, currently undergoing assessment in mid-stage clinical trials for treating glioblastoma.
Details :
IN8bio intends to use the net proceeds to fund the clinical development of its product candidates, including INB-100, an allogeneic product candidate initially developed for the treatment of patients with acute leukemia undergoing hematopoietic bone marr...
Details :
INB-200 is the first genetically engineered gamma-delta T cell therapy to be administered to patients with solid tumors. It is under phase 1/2 clinical development for the treatment of glioblastoma.
Brand Name : INB-200
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 20, 2023
Lead Product(s) :
Autologous Genetically Modified Gamma-delta T Cells,Temozolomide
Details :
INB-100, IN8bio’s DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with hematologic malignancies undergoing hematopoietic bone marrow transplantation (HSCT).
Details :
INB-400 is an autologous, genetically engineered gamma-delta T cell therapy that was recently cleared by the FDA for a Phase 2 trial targeting newly diagnosed glioblastoma multiforme (GBM).
Details :
INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation.
Reset All
